✦ The Future BetsNarrow moat

Marubeni (8002) — the future bets

Marubeni's growth over the next three years is mostly copper from one expansion, plus smaller platforms that have to grow several-fold.

Marubeni's GC2027 plan sets targets for the year to March 2028: net profit above ¥620.0 billion, core operating cash flow of ¥2,000 billion over three years and ROE of 15%1. In August 2026 it raised the investment limit to ¥1,950 billion and planned shareholder returns to ¥900 billion2. Four bets carry most of the growth.

Net profit and target (¥ bn, years to March)503.02025 actual543.92026 actual580.02027 guidanceover 6202028 targetMarubeni Integrated Report 2026, FY results and GC2027
Three years of steady steps toward the plan's target.

The largest is copper. The Centinela expansion is scheduled for completion in 2027 and would take equity production capacity to about 200,000 tonnes a year3, from about 160,0004. The fastest-growing is pharmaceutical sales, built from Sumitomo Pharma's Asian business, whose profit rose from ¥2.0 billion to ¥5.0 billion with ¥10.0 billion forecast5. The one with the clearest precedent is agri-input retail in Brazil, where Adubos Real, 80% owned, earned ¥3.7 billion6. The most ambitious is a market value target: Marubeni reached ¥10 trillion on 10 February 2026 and says it aims over the long term to rank among the global top 100, which at March 2026 took about ¥26 trillion7.

The market has doubts. The shares are 23% below their 52-week high and the market value is ¥8.09 trillion8, back below the ¥10 trillion milestone.

The company also names what it will stop doing. Its plan counts on ¥600 billion of divestments over three years9, and it describes a divestment pipeline of over ¥500.0 billion alongside a new investment pipeline of over ¥3.0 trillion10. The future bets are funded partly by exiting businesses whose growth has slowed.

The measure is net profit against the GC2027 target. Guidance of ¥580.0 billion for the year to March 202711 leaves ¥40 billion to find in the final year.

Moat trajectory: Widening

Investment capacity was raised and the copper expansion is on schedule for 2027; pharmaceuticals doubled.

The number that tests this moat
Reported
Net profit guidance against the GC2027 target
¥580.0bn guided for the year to March 2027, against over ¥620.0bn by March 2028

The plan needs about ¥40 billion more in its final year; guidance missed would put the target out of reach.

Source: Marubeni financial results, year to March 2026 ↗
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
Centinela and Two Hundred Thousand Tonnes
Centinela's expansion would give Marubeni about a quarter more copper, on a schedule its partner controls.
✦ FUTURE BET 02
Medicines in Asia
Pharmaceutical distribution in Asia is Marubeni's fastest-growing platform, and it is still under 1% of profit.
✦ FUTURE BET 03
Helena's Model in Brazil
Adubos Real is Helena's model applied to Brazil, at a tenth of the size.
✦ FUTURE BET 04
A Place in the Global Top 100
Marubeni has set itself a market-value target three times its current size, which is a promise about returns more than about business.
References
  1. ReportedMarubeni's GC2027 plan sets targets for the year to March 2028: net profit above ¥620.0 billion, core operating cash flow of ¥2,000 billion over three years and ROE of 15%.
    Marubeni Corporation, Mid-Term Management Strategy GC2027 (5 February 2025) - the review of GC2024 against its targets and the GC2027 targets for net profit, core operating cash flow, ROE, payout and capital allocation. — FY to March 2026 - FY to March 2028 · publ. 5 February 2025 · source ↗
  2. ReportedIn August 2026 it raised the investment limit to ¥1,950 billion and planned shareholder returns to ¥900 billion.
    Marubeni Corporation, Summary of Consolidated Financial Results for the three months ended June 30, 2026 (IFRS) - revenue, operating profit and net profit, segment results, progress against the full-year forecast, the balance sheet at 30 June 2026, and the revised GC2027 capital allocation and new share buyback. — April-June 2026 · publ. 3 August 2026 · source ↗
  3. ReportedThe Centinela expansion is scheduled for completion in 2027 and would take equity production capacity to about 200,000 tonnes a year, from about 160,000.
    Marubeni Corporation, Presentation Materials, June 2026 - company overview, copper equity production capacity by mine, GC2027 targets and capital allocation, and the growth record since the year to March 2021. — June 2026 · publ. June 2026 · source ↗
  4. ReportedThe Centinela expansion is scheduled for completion in 2027 and would take equity production capacity to about 200,000 tonnes a year, from about 160,000.
    Marubeni Integrated Report 2026, introduction and At a Glance - the company history from 1858 and the market positions the company states for its businesses. — 2026 · publ. 2026 · source ↗
  5. ReportedThe fastest-growing is pharmaceutical sales, built from Sumitomo Pharma's Asian business, whose profit rose from ¥2.0 billion to ¥5.0 billion with ¥10.0 billion forecast.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - net profit of major group companies by segment, with ownership and business descriptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
  6. ReportedThe one with the clearest precedent is agri-input retail in Brazil, where Adubos Real, 80% owned, earned ¥3.7 billion.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - net profit of major group companies by segment, with ownership and business descriptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
  7. ReportedThe most ambitious is a market value target: Marubeni reached ¥10 trillion on 10 February 2026 and says it aims over the long term to rank among the global top 100, which at March 2026 took about ¥26 trillion.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - capital allocation, divestments and investments, shareholder returns, dividends and buybacks, credit ratings, and the share price and market value milestones. — FY to March 2026 · publ. 1 May 2026 · source ↗
  8. ReportedThe shares are 23% below their 52-week high and the market value is ¥8.09 trillion, back below the ¥10 trillion milestone.
    Marubeni (TYO: 8002) market data - share price, market capitalisation, trailing and forward price/earnings, dividend and yield, and the 52-week range, 24 September 2026. — September 2026 · publ. 24 September 2026 · source ↗
  9. ReportedIts plan counts on ¥600 billion of divestments over three years, and it describes a divestment pipeline of over ¥500.0 billion alongside a new investment pipeline of over ¥3.0 trillion.
    Marubeni Corporation, Mid-Term Management Strategy GC2027 (5 February 2025) - the review of GC2024 against its targets and the GC2027 targets for net profit, core operating cash flow, ROE, payout and capital allocation. — FY to March 2026 - FY to March 2028 · publ. 5 February 2025 · source ↗
  10. ReportedIts plan counts on ¥600 billion of divestments over three years, and it describes a divestment pipeline of over ¥500.0 billion alongside a new investment pipeline of over ¥3.0 trillion.
    Marubeni Corporation, full-year IR presentation for the fiscal year ended March 31, 2026 - capital allocation, divestments and investments, shareholder returns, dividends and buybacks, credit ratings, and the share price and market value milestones. — FY to March 2026 · publ. 1 May 2026 · source ↗
  11. ReportedGuidance of ¥580.0 billion for the year to March 2027 leaves ¥40 billion to find in the final year.
    Marubeni Corporation, Summary of Consolidated Financial Results for the fiscal year ended March 31, 2026 (IFRS) - consolidated statements of profit or loss, financial position and cash flows, the segment note on the ten operating segments with revenue, gross trading profit, operating profit, share of profit of associates, net profit and segment assets, the investments in associates by segment, the one-time items including the Daiichi Life real-estate valuation gain, the dividend and buyback record, and the forecast for the year to March 2027 with its assumptions. — FY to March 2026 · publ. 1 May 2026 · source ↗
Sources
Generated September 24, 2026